Edition:
India

People: Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

11.60USD
7 Aug 2020
Change (% chg)

-- (--)
Prev Close
$11.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,576
52-wk High
$18.87
52-wk Low
$5.65

Yea, Christopher 

Mr. Christopher M. Yea Ph.D. serves as Chief Development Officer of the Company. Prior to joining us, he was the Chief Operating Officer at Vantia, Ltd. from its spin-out from Ferring Pharmaceuticals in 2008, until November 2015. Prior to the spin-out of Vantia, Dr. Yea led the Biology group and was responsible for transition of candidates into development at Ferring Pharmaceuticals. Following post-doctoral work he spent several years at Roussel-UCLAF and Hoechst Marion Roussel. Dr. Yea holds a B.Sc. and a Ph.D. in Biochemistry from the University of Bristol, UK.

Basic Compensation

Total Annual Compensation, USD 640,833
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 183,105
Fiscal Year Total, USD 823,938

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --